>>9041423 Q LB

SARS-COV & SARS-COV-2 Both attack the body thru the ACE2 Receptor

Simple as blocking the ACE2 Receptors?

ACE2 receptor blockers: a novel therapeutic approach for COVID-19

https://www.ersnet.org/covid-19-blog/ace2-receptor-blockers–a-novel-therapeutic-approach-for-covid-19

Angiotensin receptor blockers (ARBs) have effects that are similar to angiotensin converting enzyme (ACE) inhibitors, but ACE inhibitors act by preventing the formation of angiotensin II rather than by blocking the binding of angiotensin II to muscles on blood vessels. ARBs are used for controlling high blood pressure, treating heart failure, and preventing kidney failure in people with diabetes.Therefore, angiotensin receptor blockers (ARBs such as losartan, valsartan, telmisartan, etc) can be a novel therapeutic approach to block the binding and hence, attachment of SARS-CoV-2 RBD to ACE2-expressing cells, thus inhibiting their infection to host cells.

Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19

https://www.ncbi.nlm.nih.gov/pubmed/32356926

In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications similar to those produced by the SARS coronavirus in the 2002-2003 epidemic. This new disease was named COVID-19 and the causative virus SARS-CoV-2. The SARS-CoV-2 virus enters the airway and binds, by means of the S protein on its surface to the membrane protein ACE2 in type 2 alveolar cells. The S protein-ACE2 complex is internalized by endocytosis leading to a partial decrease or total loss of the enzymatic function ACE2 in the alveolar cells and in turn increasing the tissue concentration of pro-inflammatory angiotensin II by decreasing its degradation and reducing the concentration of its physiological antagonist angiotensin 1-7. High levels of angiotensin II on the lung interstitium can promote apoptosis initiating an inflammatory process with release of proinflammatory cytokines, establishing a self-powered cascade, leading eventually to ARDS. Recently, Gurwitz proposed the tentative use of agents such as losartan and telmisartan as alternative options for treating COVID-19 patients prior to development of ARDS. In this commentary article, the authors make the case for the election of telmisartan as such alternative on the basis of its pharmacokinetic and pharmacodynamic properties and present an open-label randomized phase II clinical trial for the evaluation of telmisartan in COVID-19 patients (NCT04355936).

ACE II blockers

https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/angiotensin-ii-receptor-blockers/art-20045009

Examples of angiotensin II receptor blockers include:

Azilsartan (Edarbi)

Candesartan (Atacand)

Eprosartan

Irbesartan (Avapro)

Losartan (Cozaar)

Olmesartan (Benicar)

Telmisartan (Micardis)

Valsartan (Diovan)